Abstract

445 Background: Stereotactic body radiation therapy(SBRT) is increasingly used in locally advanced pancreatic cancer (LAPC). SBRT can be delivered using 3D conformal, static intensity modulated radiotherapy (IMRT), and volumetric modulated arc therapy (VMAT) techniques. Prior data suggest advantages of using VMAT over IMRT for single-fraction pancreas SBRT. We performed the first dosimetric comparison of IMRT with one and two arc VMAT for 5-fraction pancreas SBRT, a more commonly used regimen. Methods: We generated 5-fraction SBRT plans for 12 LAPC patients who were previously treated at our institution with standard fractionation. The prescription dose was 33 Gy delivered in 6.6 Gy fractions. Assuming breath hold, 3 plans were generated for each patient: 9-beam static IMRT, 1-arc VMAT (VMAT1), and 2-arc VMAT (VMAT2) targeting the primary tumor. Target coverage and normal tissue doses were compared between the delivery techniques. Results: Each plan met target coverage planning goals. More VMAT2 plans (100%) were able to meet all normal tissue constraints than VMAT1 (83.3%) or IMRT (75%). Duodenal dose was most lowest for VMAT2 compared to VMAT1 and IMRT for mean dose (8.66 vs. 9.00 vs. 8.99 Gy); D4% (25.9 vs. 26.6 vs. 26.3 Gy); V10Gy (38.02 vs. 39.33 vs. 40.11%), V15Gy (23.98 vs. 25.88 vs. 25.97%), V20Gy (12.73 vs. 13.84 vs. 14.95%), and V25Gy (5.96 vs. 6.85 vs. 6.78%)(all p < 0.05). The tumors closest to the duodenum had statistically significantly improved V30Gy for VMAT2 compared to VMAT1 and IMRT (both p < 0.001). VMAT1 and VMAT2 reduced dose to the stomach, spinal cord, and liver compared to IMRT; kidney dose, however, was lowest using IMRT. VMAT2 plans had the highest conformity, but required the most monitor units to deliver. Delivery time was significantly longer with IMRT, compared to VMAT1 and VMAT2 (8.25 vs. 2.16 vs. 3.33 mins). Conclusions: These data suggest that VMAT2 should be strongly considered for 5-fraction pancreas SBRT because of superior normal tissue sparing, more conformal target volume coverage, and faster treatment delivery time (compared to IMRT). Further evaluation is needed to clarify whether the dosimetric advantages of VMAT2 are clinically significant.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call